August 27, 2026

Industry Insights

Healthcare Market Report

Banker Commentary:

Women's Health Benefit Managers: From Point Solution to Population Health Platform

Banker Commentary

Contents

Women's Health Benefit Managers: From Point Solution to Population Health Platform

Banker Commentary by Alexandra Clemens

Women's health benefits have historically centered on fertility and family-building services. However, employers are increasingly recognizing that women's health spending extends far beyond fertility and encompasses a broad range of conditions and life stages, including pregnancy and postpartum care, gynecologic conditions, menopause, pelvic health, musculoskeletal disorders, and chronic disease management.

As a result, a new category of women's health benefit managers is emerging. These organizations are evolving from fertility-focused navigation into comprehensive platforms designed to manage costs, improve outcomes, and support women across their entire healthcare journey.

This shift mirrors the evolution of specialty benefit managers in pharmacy, behavioral health, and musculoskeletal care. The winners are likely to be platforms capable of integrating navigation, care management, clinical networks, virtual care, and outcome measurement into a single employer-facing offering.

Over the past decade, fertility benefit managers emerged to address rising infertility, employee demand for assistance, and increasing employer focus on diversity and inclusion. Fertility became one of the fastest growing employer-sponsored health benefit categories and attracted significant investor interest. While there is still white space in small and mid-sized employers, growth has slowed as most large, self-insured employers already offer some form of fertility benefit. The next wave of growth will come from expanding beyond fertility into the broader women's health populations.

Fertility receives significant attention due to high-cost treatments, but the cost problem in women's health expands into areas beyond this including maternity and neo-natal care, post-partum care, pelvic health, women's MSK, menopause, chronic disease, and overall gaps in care navigation. Given the recurring and longitudinal nature of much of women's healthcare consumption, it is an attractive area for managed care. The below stats outline a few specific areas for potential cost containment across this category:

- The average cost of a pre-term birth is $49k vs. $13k for a term birth.[1]
- Urinary incontinence constitutes an estimated $19.5bn of annual direct costs in the U.S.[2]
- Women with a clinical diagnosis of menopause incur 45% more healthcare costs per year.[3]
- Globally menopause-related productivity losses amount to $810bn a year.[4]
- Four out of five people with an autoimmune disease are women.[5]

continued…

The areas outlined above support significant opportunities and potential ROI across healthcare cost containment, workforce retention, and engagement in women's health. Given this, the competitive landscape has continued to converge with companies like Progyny, Maven, Kindbody, and Carrot expanding outside of fertility benefits to offer services across these categories.

Fertility benefits created the category, but they are unlikely to define its future. The next generation of women's health benefit managers will seek to manage healthcare costs, improve outcomes, and support women across their entire care journey. Just as pharmacy benefit managers became essential infrastructure within healthcare, women's health benefit managers may become a foundational component of employer healthcare strategy over the next decade.

We invite readers to continue the conversation by listening to Cain Brothers' House Calls podcast episode, "Where Is the Market for Menopause? A Genuine Healthcare Mystery." The episode offers expert perspectives on the evolving menopause care landscape and the need for greater attention to this critical area of health.

Sources:

1. Medical cost of preterm birth: United States, 2016 | PeriStats | March of Dimes
2. PDF - WHITE PAPER 7.15 10:45a
3. Elektra Health Actuarial Study_PUBLIC
4. Confronting the taboo surrounding menopause in the workplace | Bloomberg LP
5. Women and Autoimmune Diseases - PMC

M&A Activity

Selected Recent Healthcare Transactions *($MM)*

Date	Target Name	Acquirer	EV	Enterprise Value / LTM Rev.	Enterprise Value / LTM EBITDA	Description
8/20/2026	Homeward Health	Cityblock Health (General Catalyst)	NA	NA	NA	Rural provider relationships and care model
8/18/2026	Carepoint Pharmacy	New Heritage Capital	NA	NA	NA	End-to-end access hub and dispensing pharmacy serving patients
8/18/2026	CheckedUp (Rockbridge Growth Equity)	Providence Equity Partners and Varsity Healthcare Partners	NA	NA	NA	Specialty point-of-care education and engagement platform
8/18/2026	Humata Health	R1 RCM (CD&R, Khosla Ventures, and TowerBrook Capital)	NA	NA	NA	AI-powered, touchless prior authorizations
8/18/2026	Weave Communications	Francisco Partners	$650	2.5x	NA	AI-powered patient engagement and payments platform purpose-built for healthcare practices
8/13/2026	Vetspire	Battery Ventures	NA	NA	NA	AI operating system for veterinary practices
8/13/2026	U.S. Dermatology Partners	DermCare Management (Gemini Investors, Hildred Capital Management)	NA	NA	NA	Provider of dermatology care services
8/12/2026	Relevate Health (Mountaingate Capital)	Linden Capital Partners	NA	NA	~15.0x	Healthcare commercialization platform
8/12/2026	van den Boom & Associates	Gridiron Capital Partners	NA	NA	NA	Provides life sciences companies with a full-suite, embedded outsourced back-office solution
8/11/2026	Cemplicity	Marlin Equity Partners	NA	NA	NA	Patient experience and patient-reported outcomes platform
8/6/2026	ClaimsBridge	Eir Partners Capital	NA	NA	NA	Provider of end-to-end claim and network technology solutions for TPAs, networks and employers
8/6/2026	DialysisPPO	ClaimsBridge (Eir Partners Capital)	NA	NA	NA	Cost containment for end-stage renal disease and chronic dialysis treatment
8/6/2026	Verified Clinical Trials	WindRose Health Investors	NA	NA	NA	Provider of clinical trial subject registry solutions
8/5/2026	FEI Systems	Acentra Health (Carlyle)	NA	NA	NA	Provider of cloud-based Medicaid and human services technology across post-acute care and behavioral health
8/5/2026	HealthCorum	The Difference Card (Stone Point Capital)	NA	NA	NA	Healthcare data analytics for provider quality scores, insights and navigation technology
8/4/2026	Advanced eClinical Training	Tortuga Growth Partners	NA	NA	NA	Provider of online healthcare certification and workforce development
8/4/2026	Cylinder Health	Hinge Health	$105	NA	NA	Virtual digestive healthcare provider
8/3/2026	Village Medical (Michigan Assets)	Bookmark Medical (Kinderhook Industries)*	NA	NA	NA	Seven primary care practices, a diagnostic center and independent physician organization
7/28/2026	Firefly Health	Included Health (General Atlantic and Carlyle)	NA	NA	NA	Clinically integrated health plan and advanced primary care provider

Sources: Capital IQ, Merger market, and press releases
** Denotes Cain Brothers/KeyBanc Capital Markets participation*
Transaction occurred the past week

Private Placement Activity

Selected Recent Healthcare Transactions *($MM)*

Date	Company	Investor(s)	Type	Amount	Description
8/20/2026	Cityblock Health	General Catalyst	Series E	$116	Providing care for urban Medicaid and dual-eligible members
8/20/2026	Serif Health	SEVA Growth	Minority	Undisclosed	Provider of healthcare price transparency data and intelligence
8/18/2026	Happy Health	Arch Venture Partners and OpenLoop Health	Undisclosed	$75	Develops and manufactures home sleep test device
8/11/2026	Flagler Health	Bessemer Venture Partners (lead)	Series B	$50	AI-native platform for musculoskeletal care
8/11/2026	Notable Systems	XiFin (Avista)	Series B	Undisclosed	Provider of agentic AI automation software for revenue cycle operations
8/6/2026	HealthSnap	Eastwood Capital Partners	Senior Secured Growth	$25	AI-powered virtual care management
8/4/2026	QuantHealth	Qumra Capital (lead), Pitango HealthTech, Sanofi Ventures, Artofin Venture Capital, Bertelsmann Healthcare Investments, GC Ventures, NewHealth Ventures, Shoni Top Ventures, and Esplanade Ventures	Series B	$45	AI-drive clinical trial simulation
7/30/2026	Function	General Catalyst's Customer Value Fund	Growth	$450	Preventive healthcare platform that offers comprehensive health testing and monitoring services
7/30/2026	Gravie	General Atlantic (lead)	Undisclosed	$50	Health benefits platform offering level-funded group health plans and ICHRA
7/29/2026	Flourish Health	B Capital, F-Prime, and Cherryrock Capital (co-leads)	Series A	$26	Tech-enabled provider of in-home intensive mental health care for children and young adults
7/29/2026	Roger Labs	Undisclosed	Venture	$25	AI-powered clinical documentation platform tailored for home healthcare workflows
7/23/2026	Candid Health	Sixth Street Growth (lead), Oak HC/FT, 8VC, and Y Combinator	Series D	$120	Developer of an autonomous revenue cycle automation platform for healthcare providers
7/16/2026	Bunkerhill Health	Khosla Ventures (lead), Sequoia Capital, Felicis, Optum Ventures and Y Combinator	Series B	$25	Provider of agentic AI for health systems
7/15/2026	Neko Health	Lightspeed Venture Partners (lead), O.G. Venture Partners (co-lead), Atomico, General Catalyst and Lakestar, Liberty City Ventures, Positive Sum, and BDT & MSD	Series C	$700	Preventive healthcare technology company focused on AI-powered full-body health scans and early disease detection
7/15/2026	Oura	Eli Lilly	Equity	Undisclosed	Smart wearable devices that monitor sleep, activity, recovery, stress and other biometric health data
7/13/2026	Corner Health	Oak HC/FT (lead), First Round Capital and Zigg Capital	Series A	$25	Platform that equips nurse practitioners to launch and scale their own independent primary care practices
7/8/2026	Pearl Health	Andreessen Horowitz (equity lead), Viking Global Investors, AlleyCorp, Ulysses Capital, Trinity Capital (debt)	Equity and Debt	$110	AI-powered predictive insights and financial modeling platform for primary care providers
7/7/2026	Pediatrica Health Group	Valspring Capital (lead), M33 Growth	Series B	$28	multi-site pediatric primary care organization dedicated to delivering Next Generation CareSM to families
6/25/2026	Assort Health	Menlo Ventures (lead)	Series C	$120 $1.2 bn valuation	AI agents platform for the patient journey
6/23/2026	Cadence	Spark Capital (lead), Thrive Capital, General Catalyst, Coatue, B Capital, Corewell Health Ventures, Memorial Hermann, and Duke Health	Series C	$100	Digital health company for patients with chronic conditions
6/22/2026	Ensemble Health Partners	Thoreau Group	Strategic Growth	Undisclosed	Revenue cycle management platform for healthcare companies

Sources: Capital IQ, Merger market, and press releases
** Denotes Cain Brothers/KeyBanc Capital Markets participation*
Transaction occurred over the past week

Equity Capital Markets

Market Overview

- ECM issuance remained solid this past week, in what is likely to be the last significant week of issuance activity for the month:
  - Last week: 1 IPO, 6 follow-ons, 3 converts
- IPO issuance has slowed a bit as issuers navigate the calendar between the August 8th financial staleness deadline and the proverbial "Summer Slowdown" for buyside investors in the last weeks of August → Look for IPO filings to pick up over the next couple of weeks so that issuers are in a position to launch their roadshows post-Labor Day.
- Follow-on issuance should pick-up in September as issuers are in open windows, markets near all-time highs and many 1H IPOs will be through post-deal lock-up agreements.

U.S. ECM Offerings *(LTM; IPOs, Follow-ons & Converts)*



ECM Activity *(Last 4 Weeks & YoY)*

	2026 - Last 4 Weeks			2025 - Last 4 Weeks		
	Vol ($MM)	# Deals	% Share	Vol ($MM)	# Deals	% Share
IPO	3,330	10	7%	3,530	7	13%
CONV	13,431	13	28%	10,113	15	38%
FO	32,061	26	66%	13,030	39	49%
Total	48,822	49	100%	26,673	61	100%

	2026 YTD			2025 YTD		
	Vol ($MM)	# Deals	% Share	Vol ($MM)	# Deals	% Share
IPO	129,371	70	34%	20,100	40	12%
CONV	99,285	94	26%	54,768	65	33%
FO	146,930	243	39%	88,660	179	54%
Total	375,586	407	100%	163,528	284	100%

IPO & Follow-on 1-Week Performance *(LTM)*



Most Recent Healthcare Initial Public Offerings *($MM)*

Issuer Information				Deal Sizing				Pricing		Performance	
Pricing Date	Company	Sector	Ticker	Deal Value ($MM)	Market Cap ($MM)	Deal as % of Mkt. Cap	% Primary	Offer Price	Final Range	1-Day	1-Week
5/12/2026	GMR Solutions	Healthcare Services	GMRS	$478.7	$3,347.2	14.3%	100.0%	$15.00	$22.00 - $25.00	(6.8%)	(19.5%)
5/7/2026	Mobia Medical	Medical Products	MOBI	$150.0	$496.3	30.2%	100.0%	$15.00	$14.00 - $16.00	(21.7%)	(19.7%)
4/16/2026	Alamar Biosciences	Diagnostics	ALMR	$219.9	$1,130.9	19.4%	100.0%	$17.00	$15.00 - $17.00	29.4%	42.8%
3/5/2026	MiniMed Group	Medical Products	MMED	$560.0	$5,616.3	10.0%	100.0%	$20.00	$26.00 - $30.00	(7.6%)	(17.4%)
12/16/2025	Medline	Medical Products	MDLN	$7,204.7	$38,097.8	18.9%	72.1%	$29.00	$26.00 - $30.00	41.4%	50.5%

Most Recent Healthcare Follow-on Offerings *($MM)*

Issuer Information					Deal Sizing				Pricing	Performance	
Pricing Date	Company	Sector	Deal Type	Ticker	Deal Value ($MM)	Market Cap ($MM)	Deal as % of Mkt. Cap	% Primary	Discount to File	1-Day	1-Week
8/20/2026	Aveanna Healthcare	Services	Bought	AVAH	$176.3	$2,830.0	6.2%	0.0%	(9.4%)	12.0%	-
6/16/2026	Sophia Genetics	Diagnositcs	Marketed	SOPH	$57.5	$405.8	14.2%	100.0%	(3.7%)	10.3%	10.1%
6/5/2026	Nyxoah	Medical Products	Marketed	NYXH	$95.0	$287.8	33.0%	100.0%	(40.3%)	(19.2%)	(19.2%)
5/21/2026	Medline	Medical Products	Marketed	MDLN	$2,684.5	$48,737.8	5.5%	0.0%	(1.9%)	0.0%	(0.5%)
5/11/2026	Sotera Health Group	Medical Products	Bought	SHC	$486.2	$4,400.1	11.0%	0.0%	(1.0%)	2.4%	(0.5%)

Most Recent Healthcare Convertible Debt Offerings *($MM)*

Issuer Information				Deal Sizing			Pricing	
Pricing Date	Company	Sector	Ticker	Deal Value ($MM)	Market Cap ($MM)	Deal as % of Mkt. Cap	Coupon	Premium
6/17/2026	Adaptive Biotechnologies	Diagnostics	ADPT	$345.0	$2,756.0	12.5%	0.00%	40.00%
6/17/2026	NeoGenomics	Healthcare Services	NEO	$316.3	$1,365.9	3.2%	0.75%	35.00%
2/24/2026	Tandem Diabetes Care	Healthcare Products	TNDM	$300.0	$1,838.0	16.3%	0.00%	37.50%
11/4/2025	Guardant Health	Diagnostics	GH	$402.5	$12,745.9	3.2%	0.00%	35.00%
9/16/2025	Oscar Health	Health Insurance	OSCR	$410.0	$4,842.8	8.5%	2.25%	32.50%

Sources: Bloomberg, Capital IQ, Dealogic, and Press Releases

*Note: Transactions include IPOs, follow-ons (including bought deals) and convertible offerings of $25MM or more priced on a U.S.-based exchange; Price performance includes both marketed and bought deal follow-ons; * denotes Cain Brothers / KBCM transaction; excludes SPACs and fixed price IPOs*

Transaction occurred the past week

Public Equity Indices

Equity Indices (as of August 21, 2026)

Index	Wk Open	Wk Close	Returns 52 Week	Returns Weekly
DJIA	53,732	53,277	19.0%	(0.8%)
S&P 500	7,786	7,674	20.5%	(1.4%)
NASDAQ	26,729	26,180	24.1%	(2.1%)
Russell 2000	3,068	3,018	32.7%	(1.6%)
NYSE Healthcare	28,813	29,918	24.6%	3.8%

Cain Brothers Indicies	Returns 52 Week	Returns Weekly
Acute Care	3.3%	5.7%
Alternate Site Services	(0.8%)	(0.4%)
Diagnostics	21.6%	4.8%
Distribution	16.9%	(0.8%)
Healthcare IT	(9.3%)	4.7%
Healthcare REITs	47.2%	1.4%
Managed Care	24.2%	(2.4%)
Medical Technology	1.9%	2.2%
Outsourced Services	48.2%	1.5%
Pharma Services	20.8%	7.4%
Pharmacy	28.8%	(4.2%)
Primary Care	70.1%	(2.7%)
Post-Acute Care Services	32.9%	(1.5%)
Post-Acute Care Facilities	30.4%	(1.6%)

Cain Brothers Healthcare Indices (1YR Performance)



Sources: Cain Brothers, Bloomberg, Capital IQ

High Grade, High Yield & Leveraged Loan Market

Market Summary

High Grade

- The IG primary market beat expectations following a benign CPI report, as 37 issuers priced $56.1 BN in volume.

High Yield

- The high yield market held at tepid pace last week, reaching a six-week low as rising base rates and broad market volatility brought the annual summer slowdown forward and left four issuers to tap the market for $1.7 BN in volume.

Term Loan B Market

- Technicals remain supportive, with demand continuing to outpace supply as the new-issue shrinks.

HY Index Yield & Spread (YTD)



Weekly New Issue Volume *($BN)*



New-Issue Clearing Yields[1] *($MM)*

Double-B Issuers	1Q26	2Q26	30-Day Rolling Average 08/21/26
Ba1	S+210 / 6.2%	S+214 / 5.8%	--
Ba2	S+239 / 6.5%	S+190 / 5.6%	S+200 / 5.8%
Ba3	S+220 / 6.2%	S+238 / 6.1%	S+275 / 6.6%
Single-B Issuers	**1Q26**	**2Q26**	**30-Day Rolling Average 08/21/26**
B1	S+284 / 6.6%	S+251 / 6.2%	S+228 / 6.3%
B2	S+322 / 7.0%	S+325 / 7.0%	S+356 / 7.4%
B3	S+351 / 7.3%	S+404 / 7.9%	S+332 / 7.2%

Most Recent Healthcare High-Grade Issuances *($MM)*

Date	Issuer	Security	Size	Ratings	Coupon	Maturity	Spread	IPT-Pricing
8/11/2026	Universal Health Services Inc	Sr Notes	$500	Baa3/BBB-/BBB-	600.000%	9/1/2036	+140	30 bps
8/11/2026	Universal Health Services Inc	Sr Notes	$600	Baa3/BBB-/BBB-	550.000%	9/1/2031	+113	28 bps
8/10/2026	Illumina Inc	Sr Notes	$300	Baa3/BBB/BBB	495.000%	9/19/2029	+65	25 bps

Most Recent Healthcare High-Yield Issuances *($MM)*

Date	Issuer	Security	Size	Ratings	Coupon	Maturity	Spread	Price Talk
8/10/2026	Encompass Health (add-on)	Sr. Notes	$100	Ba2/BB-/NR	587.500%	6/1/2034	148 bps	98.75 area
6/30/2026	Prestige Brands	Sr. Notes	$400	B1/BB-/NR	6.250%	7/15/2034	190 bps	6.375% area

Most Recent Healthcare Leveraged Loan Issuances *($MM)*

Date	Issuer	Ownership	Corp. Ratings	Use of Proceeds	Size	Pricing	Yield
3/19/2026	Select Medical Corporation	WCAS	B1 / B+	LBO	$100	SOFR+300, 0% @ 99	6.925%
2/5/2026	Resonetics LLC	Carlyle Group	B3 / B-	Acquisition	$220	SOFR+275, 0.75% @ 99.25	6.606%
1/29/2026	TEAM Services Group	General Atlantic	B2 / B-	LBO	$700	SOFR+525, 0% @ 99	9.171%
1/29/2026	Dechra Pharmaceuticals	EQT Partners	B2 / B-	Repricing	$834	SOFR+275, 0% @ 100	6.421%

Most Recent Healthcare Pro Rata Issuances *($MM)*

Date	Issuer	Ownership	Ratings	Use of Proceeds	Size	Pricing (in bps)	Financial Covenants
5/15/2026	VSP Optical Group, Inc.*	Private	Baa2 / NR	Refinancing	$1,500mm 5-year Revolver $1,375mm 5-year Term Loan A	Ratings-based Grid SOFR+87.5-150 Opens at SOFR+100	Max. Net Leverage Ratio: 3.75x w/ step-up to 4.25x Min. Interest Coverage Ratio: 2.50x
2/12/2026	Alkermes	Public	Ba2 / BB	Acquisition	$750mm 5-year Term Loan A	Leverage-based Grid SOFR+250-300 Opens at SOFR+275	Max. Secured Net Leverage Ratio: 4.25x Min. Interest Coverage Ratio: 2.50x

Sources: Capital IQ, Mergermarket, and press releases
** Denotes Cain Brothers/KeyBanc Capital Markets participation*
Transaction occurred over the past week

Public Finance Market

Market Overview

- The yield on the benchmark 10-year U.S. Treasury Note increased 6 bps week-over-week, closing at 4.74% on Friday. 10-year MMD increased 8 bps week-over-week.
- Healthcare Public Issuance in 2025 increased 34% vs 2024. YTD 2026 Issuance through August 21st was 25% higher than YTD 2025 through the end of August.
- Muni bond funds gained $838 MM and high yield funds gained $208 MM for the week ended August 21st.

MMD & UST Yield Curve



Weekly New Issue Volume *($MM)*



Benchmark Yields

Treasury Yields			MMD Yields			Ratio
Yr	Yield	Δ (W/W)	Yr	Yield	Δ (W/W)	MMD/ UST
2	4.24%	7 bps	2	2.51%	0 bps	59%
10	4.74%	6 bps	10	3.31%	8 bps	70%
30	5.27%	2 bps	30	4.52%	7 bps	86%

Healthcare Public Issuance Overview



Recent Healthcare Public Issuance

Healthcare Public Issuance										
Borrower/Enhancement	**Par (000s)**	**State**	**Issuer**	**Tax Status**	**LT Ratings (M/S/F)**	**Final Mat.**	**Call, Put or Reprice***	**Final Mat. Cpn.**	**YTW**	**YTM**
Recent Pricings, Week of 8/17										
Green Cay Life Plan Vil Project	192,950	FL	PBCHFA	TE	NR / NR / NR	2066	2036(C)	7.00%	7.21%	N/A
Green Cay Life Plan Vil Project	23,170	FL	PBCHFA	TE	NR / NR / NR	2032	2029(C)	5.40%	5.75%	N/A
Green Cay Life Plan Vil Project	20,800	FL	PBCHFA	TAX	NR / NR / NR	2031	2028(C)	7.75%	7.75%	N/A
Green Cay Life Plan Vil Project	11,645	FL	PBCHFA	TE	NR / NR / NR	2034	2029(C)	5.90%	6.15%	N/A
Green Cay Life Plan Vil Project	11,635	FL	PBCHFA	TE	NR / NR / NR	2033	2029(C)	5.80%	6.05%	N/A
Beacon Health System OG	75,000	IN	IFA	TE	NR / NR / NR	2066	2027(C)	7.00%	7.00%	N/A
Montage Health	25,000	CA	CSCDA	TE	NR / NR / NR	2036	NC	5.00%	3.67%	N/A
Exp. Pricings, Week of 8/24										
SSM Health	800,000	MO	SSMHCC	TAX	NR / A+ / AA-	-	-	-	-	-
SSM Health	456,940	MO	HEFASM	TE	NR / A+ / AA-	-	-	-	-	-
Adventist HealthCare	419,445	MD	MHHEFA	TE	NR / BBB / NR	-	-	-	-	-
Valley Medical Center	148,630	WA	PHDKCW	TE	A2 / NR / NR	-	-	-	-	-
Holland Community Hospital	85,585	MI	MFA	TE	NR / A+ / AA-	-	-	-	-	-

Sources: Bloomberg, TM3
** Denotes Cain Brothers/KeyBanc Capital Markets participation*
NC = No Call, MWC = Make Whole Call, (C) = Par Call, (P) = 1st Put, (R) = Reprice Date
Credit products are subject to credit approval.

Relevant News

[The Importance Of Aligning New Patient Access With High-Reliability Organization Principles]

Becker's Hospital Review | August 20, 2026

Over the past decade, healthcare organizations have increasingly adopted high-reliability organization principles to improve patient safety. The Agency for Healthcare Research and Quality, a component of the U.S. Department of Health and Human Services, defines HROs as organizations that operate in complex, high-risk environments for extended periods without catastrophic failures.

Shorter MDS Reporting Window And Growing Emphasis On Accuracy Underpin CMS' Quality Reporting Push

Skilled Nursing News | August 18, 2026

Minimum Data Set submissions are about to become a lot more complicated for skilled nursing facilities, as the Centers for Medicare & Medicaid Services places greater emphasis on the accuracy and timeliness of quality reporting while tightening the MDS reporting window in its final payment rule.

Revenue, Risk, And Regulation: Navigating CMS 2027 With AI

Healthcare Business Today | August 20, 2026

CMS reimbursement isn't keeping pace with rising costs – and new rules will eliminate many of the workarounds health systems have relied on to protect revenue. The result? A forced shift from retrospective optimization to real-time accuracy.

California Weighs Penalties For Healthcare Providers That Don't Rein In Costs

KFF Health News | August 24, 2026

California is weighing stiff penalties for hospitals and other healthcare entities that don't stay under state spending limits, potentially levying hundreds of millions of dollars in fines if these providers don't take steps to rein in rising healthcare costs.

Employers Brace For Another Year Of Healthcare Cost Increases

Fierce Healthcare | August 21, 2026

Employers' healthcare costs are set to climb yet again in 2027, with analysts at Aon projecting an increase of 9.5%.This would make for the fourth straight year in which costs increased by or close to double digits, according to the report released Thursday.

How Can Wearables Be Used In Clinical Trials? FDA Outlines Best Practices

MedTech Dive | August 21, 2026

Digital health technologies can provide insight into sleep, mobility, cardiovascular function or other aspects of a person's health in their day-to-day life.

Disclaimer

Industry Insights is compiled weekly by Cain Brothers, a division of KeyBanc Capital Markets, 1301 Avenue of the Americas, 37th Floor, New York, NY 10019; Ph: (212) 869-5600. To receive our Industry Insights email, please subscribe at key.com/newsletters. For questions regarding Industry Insights, please email rgruber@cainbrothers.com.

"Cain Brothers, a division of KeyBanc Capital Markets" is a trade name of KeyBanc Capital Markets Inc., Member FINRA/SIPC. KeyBanc Capital Markets Inc. and KeyBank National Association ("KeyBank N.A.") are separate, but affiliated companies. Securities products and services are offered by KeyBanc Capital Markets Inc. and its licensed securities representatives. Banking products and services are offered by KeyBank N.A.

This report was not issued by our research department. The information contained in this report has been obtained from sources deemed to be reliable but is not represented to be complete, and it should not be relied upon as such. This report does not purport to be a complete analysis of any security, issuer, or industry and is not an offer or a solicitation of an offer to buy or sell any securities. This report is prepared for general information purposes only.

Please read our complete KeyBanc Capital Markets disclosure statement.